Andronesi, Ovidiu C.
Esmaeili, Morteza
Borra, Ronald J. H.
Emblem, Kyrre
Gerstner, Elizabeth R.
Pinho, Marco C.
Plotkin, Scott R.
Chi, Andrew S.
Eichler, April F.
Dietrich, Jorg
Ivy, S. Percy
Wen, Patrick Y.
Duda, Dan G.
Jain, Rakesh
Rosen, Bruce R.
Sorensen, Gregory A.
Batchelor, Tracy T.
Article History
Received: 23 September 2016
Revised: 18 April 2017
Accepted: 19 April 2017
First Online: 12 June 2017
Competing interests
: T.T.B. received consulting honoraria from Merck & Co., Roche, Kirin Pharmaceuticals, Spectrum, Amgen, and Novartis; has provided CME lectures and material for Up to Date, Inc., Robert Michael Educational Institute LLC, Educational Concepts Group, Research to Practice, Oakstone Medical Publishing, American Society of Hematology, and Imedex; has consulted for Champions Biotechnology, Advance Medical; and received research support from Pfizer, Astra Zeneca, and Millennium. E.R.G. received research support from Merck. D.G.D. served as a consultant for Hexal/Sandoz. R.K.J. received research grants from MedImmune and Roche; received consultant fees from Enlight, Noxxon, and Zyngenia; owns equity in Enlight, SynDevRx, and XTuit; and serves on the Board of Directors of XTuit and Boards of Trustees of H&Q Healthcare Investors and H&Q Life Sciences Investors. The remaining authors declare no competing financial interests.